Next Article in Journal
Review of Guidelines on the Treatment of Metastatic Renal Cell Carcinoma
Previous Article in Journal
Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue s1
10.3747/co.v16i0.402
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer

by
B. Seruga
,
H. K. Gan
and
J. J. Knox
*
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(s1), 52-59; https://doi.org/10.3747/co.v16i0.402
Submission received: 11 February 2009 / Revised: 4 March 2009 / Accepted: 9 April 2009 / Published: 1 May 2009

Abstract

The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
Keywords: sunitinib; sorafenib; temsirolimus; toxicity; side effects; management sunitinib; sorafenib; temsirolimus; toxicity; side effects; management

Share and Cite

MDPI and ACS Style

Seruga, B.; Gan, H.K.; Knox, J.J. Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer. Curr. Oncol. 2009, 16, 52-59. https://doi.org/10.3747/co.v16i0.402

AMA Style

Seruga B, Gan HK, Knox JJ. Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer. Current Oncology. 2009; 16(s1):52-59. https://doi.org/10.3747/co.v16i0.402

Chicago/Turabian Style

Seruga, B., H. K. Gan, and J. J. Knox. 2009. "Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer" Current Oncology 16, no. s1: 52-59. https://doi.org/10.3747/co.v16i0.402

APA Style

Seruga, B., Gan, H. K., & Knox, J. J. (2009). Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer. Current Oncology, 16(s1), 52-59. https://doi.org/10.3747/co.v16i0.402

Article Metrics

Back to TopTop